Diuretics and Inotropic Agents in Heart Failure

Role of Diuretics: Although these drugs possess hypotensive effects, they are not primarily categorized as antihypertensives in the clinical context of heart failure. Instead, they are specifically reserved for managing the symptoms and fluid complications associated with the condition.
Pathophysiology and Rationale: Heart failure occurs when the heart is unable to keep pace with the volume of blood it is required to pump, leading to improper filling of the cardiac chambers.
- Vascular Pressure: This failure leads to an increase in pressure within the vasculature.
- Fluid Leakage: High vascular pressure forces fluid out of the blood vessels and into surrounding tissues.
- Peripheral Oedema: This occurs when fluid leaks into the peripheral tissues (e.g., legs and ankles).
- Pulmonary Oedema: This occurs when fluid leaks into the lungs, severely impacting respiration.
Universal Mechanism of Action: Diuretics alleviate fluid retention symptoms by targeting the kidneys to increase the excretion of sodium ions ( $Na^+$ ). This process reduces total blood volume and subsequently reduces preload, easing the workload on the heart.

Primary Agents: This class includes two drugs:
- Spironolactone: The much more commonly used agent.
- Adlerinone: A secondary agent in this class.
Protective Effects: Both Spironolactone and Adlerinone are noted for reducing aldosterone-induced myocardial vascular damage.
Mechanism of Action for Spironolactone:
- The drug binds to the mineralocorticoid receptor.
- It inhibits the expression of the sodium channel ( $Na^+$ channel).
- It inhibits the sodium-potassium ATPase pump ( $Na^+/K^+ \, \text{ATPase}$ ) at the collecting duct of the nephron.
- Result: This prevents sodium from being reabsorbed into the systemic circulation, leading to the increased excretion of both sodium ( $Na^+$ ) and water ( $H_2O$ ).

Frisamine (furosemide): Classified as a loop diuretic, it is recognized as the most potent diuretic available.
- Clinical Value: It is used primarily for symptomatic relief and offers morbidity benefits; however, it does not provide mortality benefits.
Mechanism of Action: Furosemide inhibits the sodium-potassium-dichloride symporter ( $Na^+/K^+/2Cl^-$ ) at the luminal membrane of the ascending loop of HETLINE.
Renal Impairment and the Dosing Paradox:
- Standard Pharmacokinetic Logic: Generally, for drugs cleared by the kidneys, the dose is reduced in renally impaired patients to prevent toxicity or further damage.
- The Furosemide Exception: Furosemide is a unique exception to this rule.
- Dependence on Filtrate: The degree of diuresis is strictly dependent on the amount of the drug that reaches the tubular lumen. The drug functions from the filtrate side (luminal side), not the basolateral membrane side.
- Dosing Strategy: In a renally impaired patient, the dose must be increased rather than decreased. If the dose is reduced, efficacy is lost because insufficient drug is cleared into the filtrate to block the symporter. Increasing the dose ensures a high enough concentration is present on the filtrate side to be effective.

Clinical Use in Heart Failure: While Digoxin is used in Arrhythmia to decrease heart rate, its role in heart failure is as a positive inotropic agent used to increase cardiac contractility.
Mechanism of Action:
- Digoxin works by inhibiting the $Na^+/K^+ \, \text{ATPase}$ pump on the cardiac membrane.
- Normal Pump Function: Under normal conditions, the pump facilitates the efflux (exit) of $3 \, Na^+$ ions for every $2 \, K^+$ ions that enter the cardiac myocytes.
- Equilibration: Usually, the loss of sodium ions is equilibrated by the efflux of calcium ( $Ca^{2+}$ ) ions.
- Inhibition Effect: By inhibiting the pump, Digoxin prevents the outflow of sodium ions from the cell.
- Result: This leads to an accumulation of sodium inside the cell, which in turn causes more calcium ions to be trapped within the cardiac myocytes.
- Outcome: The increased intracellular calcium increases cardiac contractility without causing an associated increase in myocardial oxygen demand.
Pharmacokinetic Profile and Adverse Effects:
- Therapeutic Index: Digoxin has a very narrow therapeutic index, making Therapeutic Drug Monitoring (TDM) mandatory.
- Adverse Effects: There is a high risk of toxicity. Common symptoms include:
  - Nausea and vomiting.
  - Blurred vision.
  - Confusion.
  - Bradycardia: Because it naturally reduces heart rate, it can lead to excessively slow heart rhythms.

Mirinone:
- Mechanism: Inhibits the breakdown of cyclic AMP ( $cAMP$ ).
- Effect: Leads to an increase in cardiac contractility without increasing myocardial oxygen demand.
Dobutamine:
- Classification: $\beta_1$ agonist (beta-one agonist).
- Properties: It is a sympathomimetic agent that increases cardiac contractility.
Vasodilators: These are typically reserved for patients whose heart failure is refractory (not controlled by other standard drugs).
- Avobradin: Acts as a reducer of heart rate.
- Nitrates: Act as vasodilators to specifically reduce preload.
- Hydralazine: Acts as a vasodilator to specifically reduce afterload.

Established Drug Classes:
- ACE inhibitors
- ARBs
- Armin (ARNI)
- $\beta$ -blockers (B blockers)
- Diuretics
- Digoxin
New Additions to Therapy:
- SAGL2 inhibitors (SGLT2 inhibitors)
- Soluble guanylyl cyclase stimulator
Clinical Outcomes Analysis:
- Furosemide: Confirmed to provide symptomatic relief and mobility (morbidity) benefits only.
- Predictive Exercise: Students should evaluate other classes to determine if they offer mobility benefits, mortality benefits, or both based on their specific mechanisms.

Dietary Restrictions: Patients must strictly restrict their salt (sodium) and fluid intake to avoid exacerbating fluid retention.
Weight Monitoring: It is essential for patients to perform daily weight monitoring.
- Purpose: This is not to track body fat, but to detect sudden fluid overload early.
Consequences of Non-compliance: Increased intake of salt or fluids can lead to:
- Worsening heart failure status.
- Increased peripheral edema.
- Shortness of breath.
- Deep stare (dyspnea).